insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

QSAM · Qsam Biosciences, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ4 '23Q3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21
Revenue---$0---$0--
Cost of Revenue----------
Gross Profit----------
R&D-$364.3K$448.3K$206.5K-$245.9K$204.2K$254.8K-$164.4K
SG&A-$75.0K$66.1K$68.0K-$86.9K$49.3K$119.5K-$18.8K
Total Operating Expenses-$1.16M$1.24M$1.07M-$1.21M$1.26M$1.77M-$1.20M
D&A----------
Operating Income-($1.16M)($1.24M)($1.07M)-($1.21M)($1.26M)($1.77M)-($1.20M)
Interest Expense----------
Income Tax----------
Net Income-($1.16M)($1.24M)($1.51M)-($1.23M)($1.28M)($1.79M)-($1.05M)
EPS - Basic-($0.36)($0.48)($0.90)-($0.75)($0.79)---
EPS - Diluted-($0.36)($0.79)-------

Balance Sheet

Line itemQ4 '23Q3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21
Cash & Equivalents$1.39M$446.6K$225.3K$851.4K$225.3K$899.3K$429.4K$872.1K$1.50M$1.07M
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$1.71M$610.3K$462.6K$1.29M$364.6K$965.4K$537.6K$965.1K$1.67M$1.12M
Total Assets$1.71M$610.3K$462.6K$1.29M$364.6K$965.4K$537.6K$965.1K$1.67M$1.12M
Current Liabilities$1.03M$1.71M$1.38M$1.30M$1.58M$2.66M$2.37M$1.90M$1.39M$333.3K
Long-term Debt----------
Total Liabilities$1.03M$1.71M$1.38M$1.30M$1.58M$2.66M$2.37M$1.90M$1.39M$333.3K
Stockholders' Equity$163.2K($1.84M)($1.65M)($735.3K)($1.94M)($2.41M)($2.54M)($1.64M)($416.7K)$101.9K
Retained Earnings($40.16M)($39.67M)($38.47M)($37.23M)($35.18M)($33.63M)($32.39M)($31.11M)($29.28M)($25.84M)

Cash Flow

Line itemQ4 '23Q3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21
Operating Cash Flow---($440.5K)---($627.8K)--
Investing Cash Flow----------
Financing Cash Flow---$35.0K------
CapEx----------
Free Cash Flow----------

Ratios

MetricQ4 '23Q3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets--190.8%-267.6%-116.8%--127.8%-238.7%-185.3%--94.0%
Return on equity-63.2%75.0%205.0%-51.1%50.5%109.1%--1035.0%
Return on invested capital----------
Liquidity
Current ratio1.650.360.340.990.230.360.230.511.203.37
Quick ratio1.650.360.340.990.230.360.230.511.203.37
Cash ratio1.340.260.160.660.140.340.180.461.083.20
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier10.45-0.33-0.28-1.75-0.19-0.40-0.21-0.59-4.0111.01
Liabilities / Assets0.612.802.981.014.332.764.411.970.830.30
Efficiency
Asset turnover---0.00---0.00--
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-4.6%2.0%39.8%--1.5%56.5%46.9%--192.8%
Net income growth (YoY)-5.6%3.6%15.7%--17.0%55.8%59.4%-56.5%
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-23.6%35.0%55.1%-364.8%---91.8%-

Peer comparison

Same SIC group: Specialty Cleaning, Polishing and Sanitation Preparations

CompanyRevenue (last FY)Net marginROE
CLX$7.10B11.4%252.3%
ZONE$2.07M-325.3%-459.9%
DSEY$2.77B-6.1%-25.2%
OBCI$64.30M13.1%17.7%

Comparing QSAM Biosciences against the 4 most active filers in the same SIC group.